01—Abstract
Summary
Summary of the 8-K filed December 4, 2024. Cited figures are marked; the original filing is the authoritative source.
On December 2, 2024, Cencora (NYSE: COR) priced a $1.8 billiona senior unsecured notes offering in three tranches: $500 million of 4.625% notes due 2027, $600 million of 4.850% notes due 2029, and $700 million of 5.150% notes due 2035.
The Company expects to receive net proceeds of approximately $1.79 billionb after underwriting discounts and offering expenses, with closing expected on December 9, 2024. The offering was made under a shelf registration statement filed November 26, 2024. The proceeds are earmarked primarily to finance a portion of the proposed acquisition of the majority of Retina Consultants of America, along with related fees and expenses and general corporate purposes.
The offering is not contingent on the acquisition closing, which is expected to occur after the notes sale closes. Until deployed, the Company intends to hold the proceeds in high-quality, short-term debt securities. For investors, the filing signals a material increase in debt, with the new notes representing a meaningful layer of leverage added to fund a specialty ophthalmology services deal.
The filing also discloses extensive existing banking relationships. Several underwriters, including BofA Securities, Citigroup, J.P. Morgan and Wells Fargo, serve in multiple capacities across Cencora's revolving credit facility, commercial paper program, receivables securitization facility, a new term loan facility and a 364-day revolver dated November 26, 2024, and bridge financing commitments.
As of September 30, 2024, there were no borrowings under the multi-currency revolver or receivables facility. The disclosure indicates the company is refinancing and bridging its acquisition funding through a combination of bonds, term loans and short-term facilities.
02—Key points
Key Highlights
- Priced $1.8 billion in senior unsecured notes across three maturities: $500M 4.625% due 2027, $600M 4.850% due 2029, and $700M 5.150% due 2035.
- Expected net proceeds of approximately $1.79 billion, with closing targeted for December 9, 2024.
- Proceeds earmarked to finance a portion of the proposed acquisition of the majority of Retina Consultants of America, plus fees and general corporate purposes.
- The offering is not contingent on completion of the Retina Consultants acquisition, which will close after the notes sale.
- Offering registered under a Form S-3 shelf filed November 26, 2024 (Registration No. 333-283481).
- Disclosed multiple new financing facilities dated November 26, 2024, including a term loan facility and a 364-day revolving credit facility, plus bridge financing commitments tied to the acquisition.
- As of September 30, 2024, no borrowings were outstanding under the multi-currency revolver or the receivables securitization facility.
03—Questions
Frequently Asked Questions
How much debt did Cencora raise and what are the terms?
Cencora priced $1.8 billion of senior unsecured notes: $500 million at 4.625% due December 15, 2027; $600 million at 4.850% due December 15, 2029; and $700 million at 5.150% due February 15, 2035. Net proceeds are estimated at about $1.79 billion.
What is the money being used for?
The company intends to use the net proceeds to finance a portion of its proposed acquisition of the majority of Retina Consultants of America, to pay related fees and expenses, and for general corporate purposes.
Is the bond offering dependent on the Retina Consultants acquisition closing?
No. The offering is not contingent on completion of the acquisition, which is expected to close after the notes sale closes on December 9, 2024.
Why does this filing matter for investors?
It adds roughly $1.8 billion of long-term unsecured debt, increasing leverage, and signals the scale of the Retina Consultants deal. Investors will want to watch how the acquisition is financed, its impact on leverage and interest expense, and whether it changes the company's capital allocation outlook.
Are any of the underwriters also lenders to Cencora?
Yes. BofA Securities, Citigroup, J.P. Morgan, Wells Fargo and their affiliates serve in various roles across Cencora's existing and new credit facilities, commercial paper program, receivables securitization, and bridge financing commitments, and have served as underwriters on past note offerings.
04—Continue